Wall Street analysts expect Soligenix Inc. (NASDAQ:SNGX) to report sales of $1.58 million for the current quarter, Zacks reports. Two analysts have provided estimates for Soligenix’s earnings, with the lowest sales estimate coming in at $1.50 million and the highest estimate coming in at $1.66 million. Soligenix reported sales of $1.70 million in the same quarter last year, which indicates a negative year over year growth rate of 7.1%. The company is expected to report its next quarterly earnings report on Monday, March 26th.

On average, analysts expect that Soligenix will report full-year sales of $1.58 million for the current year, with estimates ranging from $5.70 million to $5.80 million. For the next financial year, analysts expect that the business will post sales of $9.40 million per share, with estimates ranging from $9.00 million to $9.80 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Soligenix.

Soligenix (NASDAQ:SNGX) last announced its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.15. The company had revenue of $1.82 million during the quarter, compared to the consensus estimate of $1.36 million. Soligenix had a negative return on equity of 112.81% and a negative net margin of 90.93%.

A number of research analysts recently issued reports on SNGX shares. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Soligenix in a report on Thursday, September 21st. Maxim Group set a $5.00 price objective on Soligenix and gave the stock a “buy” rating in a report on Tuesday, October 24th.

Soligenix (SNGX) traded down $0.01 during trading hours on Friday, hitting $1.91. The company had a trading volume of 69,400 shares, compared to its average volume of 251,212. Soligenix has a fifty-two week low of $1.74 and a fifty-two week high of $5.08.

In related news, insider Spa Essetifin purchased 293,510 shares of the firm’s stock in a transaction on Wednesday, November 29th. The stock was purchased at an average cost of $2.12 per share, for a total transaction of $622,241.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.03% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “Soligenix Inc. (SNGX) Expected to Announce Quarterly Sales of $1.58 Million” was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/15/soligenix-inc-sngx-expected-to-announce-quarterly-sales-of-1-58-million.html.

About Soligenix

Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Get a free copy of the Zacks research report on Soligenix (SNGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.